Media stories about OptiNose (NASDAQ:OPTN) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OptiNose earned a news impact score of 0.14 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.7721947879223 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
A number of research analysts have commented on OPTN shares. Royal Bank Of Canada initiated coverage on OptiNose in a research report on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price target for the company. Piper Jaffray Companies initiated coverage on OptiNose in a research note on Tuesday, November 7th. They issued an “overweight” rating and a $27.00 price target on the stock. Jefferies Group initiated coverage on OptiNose in a research note on Tuesday, November 7th. They set a “buy” rating and a $27.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on OptiNose in a research note on Tuesday, November 7th. They set an “outperform” rating and a $29.00 target price on the stock.
Shares of OptiNose (NASDAQ OPTN) traded up $0.45 during trading on Tuesday, reaching $18.98. The company had a trading volume of 98,000 shares, compared to its average volume of 173,109. OptiNose has a one year low of $15.01 and a one year high of $21.46.
COPYRIGHT VIOLATION NOTICE: “OptiNose (OPTN) Getting Somewhat Positive Media Coverage, Analysis Shows” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/05/optinose-optn-earns-media-impact-rating-of-0-14.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Receive News & Ratings for OptiNose Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose Inc and related companies with MarketBeat.com's FREE daily email newsletter.